Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? - Wikidata - awgldk - TriplyDB

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

http://www.wikidata.org/entity/Q37644608

about

Unveiling changes in the landscape of patient populations in cancer early drug development Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer Molecular biomarker analyses using circulating tumor cells Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box.Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit Integrating transcriptomics and proteomics to show that tanshinone IIA suppresses cell growth by blocking glucose metabolism in gastric cancer cells.Design, synthesis, and evaluation of small molecule Hsp90 probes.γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.MicroRNAs as potential biomarkers in cancer: opportunities and challenges The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.Bridging the gap: moving predictive and prognostic assays from research to clinical use The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives.Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.Improving the outcomes: developing cancer therapeutics.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Targeting PI3K in Cancer: Any Good News?Circulating microRNA biomarkers for glioma and predicting response to therapy.Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?A framework for prescription in exercise-oncology research.Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.Modeling and simulation analysis of the relationship between lesion recurrence on brain images and clinical recurrence in patients with ischemic stroke.

P2860

Q28073826-BC6E11DB-643F-4BF9-81E1-427AD6590A41 Q28741689-55030FE6-5F11-435F-A0E0-153DBA206FF3 Q28749394-5D1FEA2D-26CE-44F2-9006-0BA1024854BF Q33876854-986CE4D1-4B24-49FA-BBB7-57CFFC218A8A Q34113504-F753EE2C-68FF-41C3-BF2B-64D39E140418 Q34122784-40A87655-5F8F-454C-B69C-B4CA29E0437A Q35083386-D11D1F11-728F-43BC-979A-1D114AADFD6F Q35128528-419002EF-9005-4F22-B675-E165787E2017 Q35201518-D8911CB6-1BED-456A-8744-7732E9A144CD Q35271157-28D8F697-7AF4-47E4-804D-54D974B07F2B Q35274955-A6054292-234E-4B2A-9CD8-1F26E9353A35 Q35838577-565A945A-7987-4963-85AC-9B5D3075DAB3 Q36771796-64A5B3A7-C3F5-4CB2-AA35-5316D853050C Q36871155-D52AC94C-3EBC-4D69-A48D-592F56C94BF9 Q37798159-ACBEC028-A79A-4117-A99D-10FD5FF005C7 Q37825614-216F082D-5126-45AB-82EB-36E8781C1609 Q37826009-C1245941-1CAF-49BA-8085-F0D2AD22E12B Q37965556-B08ECE8C-0B5A-4B50-9C7B-AF2985893EF4 Q38042638-E2EA4C66-ACF6-4CA7-84E0-D0F7AAF47D92 Q38105322-10CAD2A9-F7C1-4EDB-A10C-4B410028EA23 Q38201683-F8F0AE1B-C505-4998-8BED-9B12CBB264CF Q38667456-97EEA585-4AF9-400A-898F-BE046FBE32C9 Q42652182-B3F42739-BDB0-4A50-AAF9-6C54EE5462C3 Q44100364-55077FAD-6B7C-43BD-BE26-AD24C88B85A2 Q48459513-4D58F465-2F70-49AC-A1C2-AF32FA88799C

P2860

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

http://www.wikidata.org/entity/Q37644608

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Can molecular biomarker-based ...... e anticancer drug development?

@en

Can molecular biomarker-based ...... e anticancer drug development?

@nl

type

label

Can molecular biomarker-based ...... e anticancer drug development?

@en

Can molecular biomarker-based ...... e anticancer drug development?

@nl

prefLabel

Can molecular biomarker-based ...... e anticancer drug development?

@en

Can molecular biomarker-based ...... e anticancer drug development?

@nl

P1433

Q37644608-2B5F207F-5FC5-45FB-865E-7309A063A22C

P1476

Q37644608-D464AC19-4DBC-4AA1-95EB-9FA8212C6E0E

P2093

Q37644608-2C1F8961-0458-401C-86C1-35CC711C709E

Q37644608-4992E8BB-C743-4B24-9606-AC470F248D69

Q37644608-516D3F2F-7CBE-4783-A73D-8E1E4AD30ECF

Q37644608-6648174D-951C-42DE-A9B0-EA986AD1DFA5

Q37644608-66DF3B68-9C23-45D2-9A1E-0ED7365CB08A

Q37644608-8CAFCA73-BEB8-4C3F-A098-817A9201C9C6

Q37644608-A6CCCFAF-3764-4EA9-A3C5-7D8D13CA1D25

Q37644608-AAB7918E-6298-4760-9D5F-C409E2E91D68

Q37644608-FBACEA46-116D-4E82-B15F-98FF26D64337

P304

Q37644608-ACC0438C-257E-467D-A038-A8450A111798

P31

Q37644608-963AF587-CB7A-4566-9365-B2D09E11D7F7

P356

Q37644608-7041754B-5D23-4B80-A40F-A91EE1A9D593

P433

Q37644608-83DECBA8-60A7-4B63-AD5B-FC6144C358F6

P478

Q37644608-61EB1474-9286-4DEC-B741-E519989CFB20

P50

Q37644608-4A882DAE-745D-48C3-9D7F-1ACF305B63C8

Q37644608-A90A68C2-217A-4D0D-BC88-6CCC95F47129

Q37644608-C7B95AA1-A3B7-4BAE-9044-95A130187DB4

P577

Q37644608-E5114308-53CA-4C44-81BB-F33310424ED5

P5875

Q37644608-E362CFC0-524E-4421-8285-17A06B6CCBAB

P698

Q37644608-BEC502F0-9CDF-433A-BAD4-736FFDBE577E

P921

Q37644608-48AED694-AFB6-41B2-88BE-E32F8D430710

Q37644608-744C0FA0-F28A-413A-AF7C-664CD6251C44

Q37644608-8A530BE8-5F9D-4680-ADAB-2AE4C5B1FB11

P356

J.DRUDIS.2009.11.006

P1433

Drug Discovery Today

P1476

Can molecular biomarker-based ...... e anticancer drug development?

@en

P2093

Craig P Carden

http://www.w3.org/2001/XMLSchema#string

Debashis Sarker

http://www.w3.org/2001/XMLSchema#string

George V Thomas

http://www.w3.org/2001/XMLSchema#string

Gerthardt Attard

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Michelle D Garrett

http://www.w3.org/2001/XMLSchema#string

Sophie Postel-Vinay

http://www.w3.org/2001/XMLSchema#string

Stan B Kaye

http://www.w3.org/2001/XMLSchema#string

Timothy A Yap

http://www.w3.org/2001/XMLSchema#string

P304

88-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUDIS.2009.11.006

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Sophie Postel-Vinay

P577

2009-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40448949

http://www.w3.org/2001/XMLSchema#string

P698

19961955

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial